BeyondSpring (NASDAQ:BYSI) Shares Up 0% – Still a Buy?

Shares of BeyondSpring Inc. (NASDAQ:BYSI) traded up 0% during trading on Tuesday . The company traded as high as $0.7556 and last traded at $0.7403. 15,701 shares changed hands during trading, a decline of 84% from the average session volume of 96,180 shares. The stock had previously closed at $0.74.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of BeyondSpring from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

BeyondSpring Stock Up 3.6%

The company has a 50-day moving average of $0.85 and a 200-day moving average of $1.35. The company has a market cap of $30.96 million, a PE ratio of -6.24 and a beta of 0.06.

BeyondSpring (NASDAQ:BYSI) last posted its earnings results on Friday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.52.

BeyondSpring Company Profile

BeyondSpring Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a selective immunomodulating microtubule-destabilizing agent designed to stimulate the immune system while affecting tumor-cell biology.

BeyondSpring has evaluated plinabulin for the prevention of chemotherapy-induced neutropenia, a potentially serious complication of cancer treatment, and for use in combination with other therapies in oncology, including treatment approaches for non-small cell lung cancer.